Guinea-Bissau

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Sanofi-aventis & EPIVAC

EPIVAC (from EPIdemiology & VACcinology) is a comprehensive, one-year, on-the-job professional training program in epidemiology, applied computing, vaccinology and management of health programs for public health officers in West Africa, culminating in an inter-university diploma in 'Organization and Management of Public Immunization Programs in Developing Countries' awarded by the universities of Cocody-Abidjan (Ivory Coast) and Paris-Dauphine (France). The program is a Sanofi Pasteur, the vaccines division of sanofi-aventis, contribution to the GAVI Alliance.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Novo Nordisk: Differential Pricing on Insulin

Among the targets for UN Millennium Development Goal 8 is a call for partnerships with pharmaceutical companies to provide access to affordable essential drugs in developing countries. Since 2001, Novo Nordisk has offered human insulin to the public health systems in Least Developed Countries (LDCs) at prices which do not to exceed 20% of the average price in Europe, Japan and North America. In 2009, Novo Nordisk offered this pricing scheme to all 49 LDCs, of which 36 used it to buy insulin at or below this price, compared to 32 in 2008.

Merck Mectizan Donation Program

Onchocerciasis, or river blindness, is a leading cause of infectious blindness in the developing world. The Merck Mectizan Donation Program (MDP) was launched in 1987, when Merck & Co., Inc. announced that it would donate Mectizan (ivermectin), for the treatment of onchocerciasis to all who needed it for as long as needed.

Merck & Co., Inc. HIV/AIDS Programs - Africa

In 2009, with support from The Merck Company Foundation, the Earth Institute at Columbia University launched a community health worker training program to strengthen community health services for over 400,000 people in 10 African countries as part of the Millennium Villages project. The initiative aims to develop a professional cadre of 800 community health workers to fill a critical gap in primary healthcare provision for rural communities throughout Africa.

LEEM Quality Control Program

Counterfeit and substandard medicines are a major threat to health in developing countries, many of which lack the technical resources to identify inferior quality medicines. To help alleviate this situation, the association representing the R&D pharmaceutical industry in France, Les Entreprises du Medicament (LEEM), started a program in 2006 to allow developing countries to send samples of suspect medicines to France for analysis. To ensure impartiality, the LEEM pays for samples to be analyzed by an independent expert body, the Central Humanitaire Medico Pharmaceutique (CHMP).

International Trachoma Initiative (ITI)

The International Trachoma Initiative (ITI) is the only organization dedicated solely to the elimination of blinding trachoma.

Global Pharma Health Fund

The Global Pharma Health Fund e.V. (GPHF) is a charitable organization initiated and funded exclusively by donations from Merck KGaA, Darmstadt Germany. In 2007, it took over the work of the former German Pharma Health Fund, which was set up in 1985. The organization aims to improve health care in the context of development assistance, in particular the use of the GPHF-Minilab in the fight against counterfeit drugs.

Global Alliance to Eliminate Lymphatic Filariasis (GAELF)

The Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was created to eliminate one of the world's leading causes of disability and disfigurement as a public health problem by the year 2020. An estimated 120 million people in at least 80 countries of the world suffer from the disease, and one billion (20% of the world's population) are at risk of infection.

Pages